1. Introduction

   • Masaki Kitajima

   EditorialNotes 05 February 2009 Pages: 1 - 2

2. S-1 review from preclinical pharmacology

   • Masakazu Fukushima

   Review Article 05 February 2009 Pages: 3 - 9

3. Adjuvant chemotherapy with 5-FU or regimens including oral fluoropyrimidine for curable gastric cancer

   • Mitsuru Sasako

   Review Article 05 February 2009 Pages: 10 - 15

4. Prediction of clinical outcome of S-1-based chemotherapy for gastric cancer patients

   • Wataru Ichikawa
   • Yasutsuna Sasaki

   Review Article 05 February 2009 Pages: 16 - 22

5. Prediction of S-1-induced anemia

   • Hyun Cheol Chung

   Review Article 05 February 2009 Pages: 23 - 30

6. Combination chemotherapy of S-1 and taxanes in Korea

   • Yeul Hong Kim
   • Hoon-Kyo Kim

   Review Article 05 February 2009 Pages: 31 - 37

7. Phase I/II studies of combination chemotherapy with S-1 and platinum in patients with previously untreated metastatic or recurrent gastric cancer

   • Yoon-Koo Kang

   Review Article 05 February 2009 Pages: 38 - 42

8. JCOG trials of systemic chemotherapy for unresectable or recurrent gastric cancer

   • Narikazu Boku

   Review Article 05 February 2009 Pages: 43 - 49

9. Clinical development of S-1 plus cisplatin therapy as first-line treatment for advanced gastric cancer

   • Wasaburo Koizumi

   Review Article 05 February 2009 Pages: 50 - 54

10. Combination therapy with S-1 and irinotecan (CPT-11) for advanced or recurrent gastric cancer

    • Hiroya Takiuchi

    Review Article 05 February 2009 Pages: 55 - 59

11. Future perspectives of chemotherapy for advanced gastric cancer

    • Atsushi Ohtsu
    • Nozomu Fuse
    • Toshihiko Doi

    Review Article 05 February 2009 Pages: 60 - 66